Patricia Inacio, PhD,  science writer—

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Sanofi’s BTK inhibitor candidate tolebrutinib for the treatment of adults with nonrelapsing secondary progressive multiple sclerosis (SPMS). According to Sanofi, tolebrutinib is the first investigational BTK inhibitor with the ability to reach the brain…

A PhD student at the UMass Chan Medical School will use funding from a newly awarded fellowship to advance his research into the mechanisms used by cells to repair myelin, the protective sheath around nerve cells that’s damaged in multiple sclerosis (MS) and other demyelinating conditions. The ongoing…

The U.S Food and Drug Administration (FDA) authorized an investigational new drug application from Synaptogenix, clearing the company to launch a clinical trial to test whether its lead candidate bryostatin-1 can prevent cognitive decline in people with multiple sclerosis (MS). The open-label, Phase 1 clinical trial (NCT06190912),…

Cionic has added three renowned institutions on the East Coast to its national Centers of Excellence program, a move that expands the availability in the U.S. of the Neural Sleeve to people with multiple sclerosis (MS) and other neurological conditions that affect mobility. The program represents a key…

Most patients with nonactive secondary progressive multiple sclerosis (SPMS) who took foralumab nasal spray for at least six months saw a decrease in microglial activity in their brains, according to its developer Tiziana Life Sciences. The results were gleaned from PET imaging data from 10 nonactive SPMS patients…

Renowned experts in multiple sclerosis (MS) healthcare, research, and advocacy will again gather at the annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC), slated this year for May 29 to June 1. The event, now in its 38th edition, will return to the Music City Center, in Nashville,…

Helius Medical Technologies is collaborating with Lovell Government Services to make its PoNS device — designed to improve walking ability in people with multiple sclerosis (MS) — available to U.S. veterans and MS patients in other federal healthcare systems. The PoNS device, officially named the Portable Neuromodulation Stimulator, is…

FSD Pharma has entered an agreement to launch a Phase 1 clinical trial that will test multiple ascending doses of Lucid-21-302 — an oral treatment candidate commonly known as Lucid-MS, for all types of multiple sclerosis (MS) — in healthy volunteers. The company’s subsidiary Huge Biopharma Australia established…

The French company Juvisé Pharmaceuticals has acquired the rights to develop and market the approved multiple sclerosis (MS) therapy Ponvory (ponesimod) outside the U.S. and Canada. The global rights were acquired from Actelion Pharmaceuticals, the therapy’s original developer and now part of Johnson & Johnson Innovative Medicine.

The U.S. Food and Drug Administration has designated SetPoint Medical’s neurostimulator a breakthrough device for the treatment of relapsing-remitting multiple sclerosis (RRMS). This designation is intended to accelerate the development of devices intending to more effectively treat or diagnose life-threatening or chronically debilitating diseases than standard approaches.

Fatigue is a significant predictor of worse health-related quality of life in adults with relapsing-remitting multiple sclerosis (RRMS), a study reports. High levels of fatigue were significantly linked with worse physical and mental health, including cognitive impairments, depression, and anxiety. The findings suggest…

Tyruko (natalizumab), the first biosimilar of Tysabri, is now available in Germany for adults with highly active relapsing-remitting multiple sclerosis (RRMS). As a biosimilar, Tyruko has the same safety and efficacy profile, mechanism of action, and pharmacological properties as Tysabri. Biosimilars are typically sold at lower prices than their reference medication,…

Rocco Mangel, the founding partner of Rocco’s Tacos & Tequila Bar, is joining the Walk MS: West Palm Beach 2024, in Florida, to raise funds for the National Multiple Sclerosis Society (NMSS). Walk MS events, taking place in numerous locations in the U.S., focus on raising disease…

The U.S. Patent and Trademark Office (USPTO) has notified Vanda Pharmaceuticals that it will grant a new patent covering the use of Ponvory (ponesimod), an approved oral treatment for relapsing forms of multiple sclerosis (MS), that will span nearly two decades, the company announced. The upcoming patent specifically…

Living with the human immunodeficiency virus (HIV) is linked to a significantly lower rate of developing multiple sclerosis (MS) — including among people exposed to antiretroviral treatment, or medicines that can stop the HIV virus from replicating — a new study found. The rate of MS was particularly reduced…

Sudo Biosciences has raised $116 million in a Series B financing to support the clinical development of two inhibitors of the TYK2 enzyme for treating neurological conditions like multiple sclerosis (MS) and skin-related diseases. One of the TYK2 inhibitors, given orally, is designed to efficiently reach the brain…

The rate of brain atrophy, or shrinkage, and changes in brain lesion volume in the first years of treatment with Rebif (interferon beta-1a) may help predict which patients with early multiple sclerosis (MS) will receive a clinically definite diagnosis, a study suggests. The brain radiologic measures may also…

Tiziana Life Sciences has dosed the first patient in a Phase 2a clinical trial testing its foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS). The trial will include about 54 participants, enrolled across six clinical sites. Patients will be randomly assigned to receive one of two…

The risk of falling among people with multiple sclerosis (MS) seems to be associated with a combination of personal, environmental, and activity-related factors, according to a large U.S. survey. Personal factors included poor balance, muscle weakness, and fatigue. Surface conditions and distraction made up environmental factors, while work-related factors…

Vanda Pharmaceuticals has acquired the U.S. and Canadian rights to Ponvory (ponesimod), an oral therapy approved for relapsing types of MS, in a new deal with Actelion Pharmaceuticals. Under the terms of the agreement, Vanda paid $100 million to Actelion (now part of Janssen), the therapy’s original developer. While…

Adhering to an aerobic exercise program of moderate to intense cycling for 12 weeks significantly eased pain and fatigue in people with multiple sclerosis (MS), allowing them to be more active in daily life, a small pilot clinical trial found. Results were similar for patients in the trial’s forced…

InSilicoTrials (IST) has received this year’s Innovation Radar Prize for its efforts to harness artificial intelligence (AI) to advance clinical trials and predictive technologies that may benefit people with multiple sclerosis (MS) and other diseases. Launched in 2015 by the European Commission, the award recognizes European Union (EU)-funded…

In children with pediatric-onset multiple sclerosis (POMS), poor sleep quality is linked to fatigue, depression, and worse quality of life, a study has found. While no significant differences in sleep measures were identified between children and adolescents with MS compared with those without the neurodegenerative condition, sleep can have…

Losing the sense of smell is associated with a higher likelihood of worse disease outcomes for people with multiple sclerosis (MS), according to a six-year follow-up study. Specifically, patients who are getting worse at identifying and discriminating odors are at higher risk of disability worsening, relapse-independent MS progression, and…

Nabiximols, the cannabis-based oral spray sold as Sativex, is available for reimbursement as an add-on therapy for moderate to severe spasticity in adults with multiple sclerosis (MS) in Ireland who failed to respond as intended to other spasticity medications. Marked by muscle stiffness and involuntary spasms or twitches,…

Vidofludimus calcium (IMU-838), an investigational oral therapy being developed by Immunic Therapeutics for all types of multiple sclerosis (MS), has demonstrated neuroprotective effects in people with progressive forms of the disease, interim clinical trial data show. The experimental therapy was associated with reductions in neurofilament light chain (NfL)…

People with multiple sclerosis (MS) who switch between more than two disease-modifying therapies (DMTs) have a higher risk of relapses compared with those who never switch, regardless of how well these patients adhere to their prescribed medications, according to real-world study in Canada. These findings are consistent with…

Assessing a person’s daily walking patterns using the Google Maps Timeline tool may help doctors remotely monitor fatigue, walking ability, and disease severity in people with multiple sclerosis (MS), a study suggests. The digital tool is built in the smartphone application Google Maps and records daily walking distance and…

FSD Pharma’s Lucid-21-302 — an oral treatment candidate known as Lucid-MS, for all types of multiple sclerosis (MS) — was found safe and well tolerated across multiple doses in healthy volunteers, according to interim data from a Phase 1 clinical trial. The newly released data are from the…

Using disease-modifying therapies (DMTs) doesn’t reduce fatigue levels in people with multiple sclerosis (MS), a study in Norway suggests. Anxiety and depression were both associated with fatigue, suggesting “there are other underlying causes of fatigue than focal inflammation, on which DMTs have an effect,” the study’s researchers wrote…